

Bericht der AG “Erworbbene Hämophilie”

Auf der GTH Mitgliederversammlung

Bremen, 21.02.2020

Bericht der AG "Erworbene Hämophilie"

Regular Article

CLINICAL TRIALS AND OBSERVATIONS

Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study

Andreas Tiede,¹ Robert Klamroth,² Rüdiger E. Scharf,³ Ralf U. Trappe,^{4,5} Katharina Holstein,⁶ Angela Huth-Kühne,⁷ Saskia Gottstein,² Ulrich Geisen,⁸ Joachim Schenk,⁹ Ute Scholz,¹⁰ Kristina Schilling,¹¹ Peter Neumeister,¹² Wolfgang Miesbach,¹³ Daniela Manner,¹⁴ Richard Greil,¹⁵ Charis von Auer,¹⁶ Manuela Krause,¹⁷ Klaus Leimkühler,¹⁸ Ulrich Kalus,¹⁹ Jan-Malte Blumtritt,¹ Sonja Werwitzke,¹ Eva Budde,²⁰ Armin Koch,²⁰ and Paul Knöbl²¹

BLOOD 2015

Regular Article

CLINICAL TRIALS AND OBSERVATIONS

Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study

Andreas Tiede,¹ Christoph J. Hofbauer,² Sonja Werwitzke,¹ Paul Knöbl,³ Saskia Gottstein,⁴ Rüdiger E. Scharf,⁵ Jürgen Heinz,⁶ Jürgen Groß,⁷ Katharina Holstein,⁸ Christiane Dobbelstein,¹ Fritz Scheiflinger,² Armin Koch,⁹ and Birgit M. Reipert²

BLOOD 2016

Journal of Thrombosis and Haemostasis, 14: 940–947

DOI: 10.1111/jth.13304

ORIGINAL ARTICLE

Diagnostic and prognostic value of factor VIII binding antibodies in acquired hemophilia A: data from the GTH-AH 01/2010 study

S. WERWITZKE, * U. GEISEN, † U. NOWAK-GÖTTL, ‡ H. EICHLER, § B. STEPHAN, § U. SCHOLZ, ¶ K. HOLSTEIN, ** R. KLAMROTH, †† P. KNÖBL, ‡‡ A. HUTH-KÜHNE, §§ B. BOMKE ¶¶ and A. TIEDE *

J Thromb Haemost 2016

ORIGINAL ARTICLE

jth

Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study

Halet Türkantoz¹ | Christoph Königs² | Paul Knöbl³ | Robert Klamroth⁴ |
Katharina Holstein⁵ | Angela Huth-Kühne⁶ | Jürgen Heinz⁷ | Hermann Eichler⁸ |
Andreas Tiede¹ 

J Thromb Haemost 2019

Bericht der AG "Erworbene Hämophilie"

Regular Article



THROMBOSIS AND HEMOSTASIS

Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A

Joerg Kahle,¹ Aleksander Orlowski,¹ Diana Stichel,¹ John F. Healey,² Ernest T. Parker,² Marc Jacquemin,³ Manuela Krause,⁴ Andreas Tiede,⁵ Dirk Schwabe,¹ Pete Lollar,² and Christoph Königs¹

BLOOD 2017

ORIGINAL ARTICLE



Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia

Andreas Tiede¹  & Andrew Worster²

Ann Hematol 2018

Bericht der AG “Erworbene Hämophilie”

Neue Daten zum Blutungsrisiko

Holstein et al. „Bleeding and response to haemostatic therapy in acquired hemophilia A: results from the GTH-AH study“

Freitag 8:30 Uhr Raum Borgwardt

Manuskript in Revision (BLOOD)

Bericht der AG “Erworbene Hämophilie”

- **Investigator-initiated clinical trial**
Emicizumab as a prophylactic agent in AHA
- Endpunkte
 - Zahl klinisch relevanter Blutungen
 - Verzicht auf immunsuppressive Therapie
 - Morbidität
 - Mortalität
- Kontakt: gerinnung@mh-hannover.de